Sugi Predict

Sugi Predict / Targets / CCNH

CCNH

Cyclin-H · P51946 · CCNH on Sugi Atlas →

93,332 patent compounds predicted against CCNH, 64,439 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL786323 SCHEMBL786323 0.58 15/20
SCHEMBL517413 SCHEMBL517413 0.54 15/20
SCHEMBL558222 SCHEMBL558222 0.53 15/20
SCHEMBL558223 SCHEMBL558223 0.53 15/20
SCHEMBL786603 SCHEMBL786603 0.62 14/20
SCHEMBL559356 SCHEMBL559356 0.51 14/20
SCHEMBL559412 SCHEMBL559412 0.54 13/20
SCHEMBL559413 SCHEMBL559413 0.54 13/20
SCHEMBL785897 SCHEMBL785897 0.69 11/20
SCHEMBL786343 SCHEMBL786343 0.64 11/20
SCHEMBL785935 SCHEMBL785935 0.60 11/20
SCHEMBL84411 SCHEMBL84411 0.50 11/20
SCHEMBL785871 SCHEMBL785871 0.54 10/20
SCHEMBL517461 SCHEMBL517461 0.54 10/20
SCHEMBL785963 SCHEMBL785963 0.54 10/20
SCHEMBL558878 SCHEMBL558878 0.51 10/20
SCHEMBL786533 SCHEMBL786533 0.50 10/20
SCHEMBL268925 SCHEMBL268925 0.46 10/20
SCHEMBL269583 SCHEMBL269583 0.46 10/20
SCHEMBL786867 SCHEMBL786867 0.81 9/20

Clinical trials — most relevant to CCNH by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) PHASE3COMPLETED
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas PHASE2RECRUITING
Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma PHASE2COMPLETED
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer PHASE2COMPLETED
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer PHASE2WITHDRAWN
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) PHASE1/PHASE2RECRUITING
Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC PHASE2ACTIVE_NOT_RECRUITING
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer PHASE2RECRUITING
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma PHASE1/PHASE2RECRUITING
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6 PHASE2RECRUITING
LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) PHASE2COMPLETED
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression PHASE2COMPLETED
BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors PHASE2WITHDRAWN
An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. PHASE1/PHASE2COMPLETED
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers PHASE1COMPLETED
Study of FCN-437c in Patients With Advanced Solid Tumors PHASE1COMPLETED
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors PHASE1RECRUITING
Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA PHASE1RECRUITING
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma EARLY_PHASE1RECRUITING
The Use of Immunohistochemical Staining for the Prediction of Wilms Tumour Progression and Recurrence nanUNKNOWN
the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy nanUNKNOWN
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer nanCOMPLETED
Prevalence of Dysplasia of the Gastric Cardia nanCOMPLETED
A Clinical Evaluation of Everolimus Eluting Coronary Stents in the Treatment of Patients With ST-segment Elevation Myocardial Infarction: EXAMINATION Study nanCOMPLETED
Study of Tissue and Blood Samples From Patients With Low-Grade Glioma nanCOMPLETED
Co'Moon for Supporting Breast Cancer Patients on Adjuvant Endocrine Therapy nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CCNH binder may also engage these)

ProteinNameSimilarity
Q9R1A0 — 0.999 Q9R1A0 →
Q4R7U4 — 0.999 Q4R7U4 →
Q61458 — 0.998 Q61458 →
Q3ZBL9 — 0.997 Q3ZBL9 →
Q10D80 — 0.978 Q10D80 →
P51947 — 0.968 P51947 →
P25008 — 0.967 P25008 →
Q16JA2 — 0.962 Q16JA2 →
Q7QB13 — 0.962 Q7QB13 →
Q29AI1 — 0.961 Q29AI1 →
P28749 — 0.961 P28749 →
Q8BM85 — 0.960 Q8BM85 →
Q8TEA7 — 0.959 Q8TEA7 →
Q52QT8 — 0.959 Q52QT8 →
Q5BBA8 — 0.959 Q5BBA8 →
Q1EAW8 — 0.958 Q1EAW8 →
Q5F361 — 0.958 Q5F361 →
D3ZS28 — 0.957 D3ZS28 →
Q4WZT9 — 0.956 Q4WZT9 →
A1C7R6 — 0.955 A1C7R6 →
Q62245 — 0.955 Q62245 →
Q2HJF3 — 0.954 Q2HJF3 →
Q9C1M4 — 0.954 Q9C1M4 →
P29994 — 0.954 P29994 →
SNRNP200 U5 small nuclear ribonucleoprotein 200 kDa helicase 0.954 landscape →
CCNE2 G1/S-specific cyclin-E2 0.954 landscape →
Q9UPW5 — 0.954 Q9UPW5 →
SOS1 Son of sevenless homolog 1 0.953 landscape →
Q6P4T2 — 0.953 Q6P4T2 →
Q6NRC7 — 0.953 Q6NRC7 →